| Vol. 6.30 – 30 August, 2021 |
| |
|
|
| The authors reported a method to generate developmentally relevant human heart organoids by self-assembly using human pluripotent stem cells. Heart organoids were comparable to age-matched human fetal cardiac tissues at the transcriptomic, structural, and cellular levels. [Nature Communications] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers generated reactive oxygen species (ROS)-sensitive fluorescent sensors targeted to different subnuclear compartments in neonatal rat ventricular cardiomyocytes, which allowed them to determine the spatial localization of ROS in cardiomyocyte nuclei upon manipulation of mitochondrial respiration. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists developed a homozygous NaV1.5 knockout induced pluripotent stem cell (iPSC) line able to differentiate into cardiomyocytes with CRISPR/Cas9 tool. The NaV1.5 KO iPSC-cardiomyocytes exhibited an organized contractile apparatus, spontaneous contractile activity, and electrophysiological recordings confirmed the major reduction in total Na+ currents. [Scientific Reports] |
|
|
|
| The authors demonstrated that protocatechuic acid treatment significantly downregulated the expression of cardiac hypertrophic markers, cardiomyocyte size, heart weight to body weight ratio, cross-sectional area, and thickness of left ventricular septum and posterior wall. [Scientific Reports] |
|
|
|
| | Human induced pluripotent stem-derived skeletal muscle cells from a healthy donor and Becker Muscular Dystrophy patients were utilized to study dystrophin in muscular dystrophy post-translational modifications and associated proteins. [Genome Medicine] |
|
|
|
| Investigators identified Krüppel-like factor 5 (KLF5), a zinc-finger transcription factor, as a key mediator of the early muscle atrophy program. KLF5 was up-regulated in atrophying myotubes as an early response to dexamethasone or simulated microgravity in vitro. [Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| Scientists described the microtubule-associated protein, MACF1, as an essential and evolutionary conserved regulator of myonuclei positioning and maintenance, in cultured mammalian myotubes, in Drosophila muscle, and in adult mammalian muscle using a conditional muscle-specific knockout mouse model. [eLife] |
|
|
|
| Sestrin2 (SESN2), a stress-inducible protein, was shown to act as a key protective signal involved in the crosstalk therein. SESN2 expression was induced in the gastrocnemius two weeks post denervation, which was accompanied by endoplasmic reticulum stress, mitochondrial dysfunction, and apoptosis. [Cell Death & Disease] |
|
|
|
| Researchers reported that the chromatin remodeler CHD4, a member of the nucleosome remodeling and deacetylase repressive complex, was essential for the expansion and regenerative functions of satellite cells. [Stem Cell Reports] |
|
|
|
| Investigators combined gene expression and non-targeted metabolomic profiling of myoblasts exposed to wasting conditions to derive a more complete picture of the myoblast response to wasting factors. [Experimental Cell Research] |
| |
|
|
| In vitro Axl inhibition by R428 and Axl knock-down inhibited growth factor-driven proliferation and migration of non-pulmonary arterial hypertension and pulmonary arterial hypertension pulmonary arterial smooth muscle cells. [Communications Biology] |
|
|
|
| Researchers explored the role of tumor necrosis factor-α-induced protein 8-like 2 (TIPE2) in the regulation of airway smooth muscle cells, which was one of the main effector cells in the development of asthma. [Respiratory Research] |
|
|
|
| THP-1/oxidized low-density lipoprotein (ox-LDL) Exo significantly increased the expression levels of CDK2 and proliferative cell nuclear antigen in human vascular smooth muscle cells, while these effects were reversed following LIPCAR silencing. [Biochemical and Biophysical Research Communications] |
|
|
|
|
| The authors provide an overview of state-of-the-art studies, challenges that have not yet been overcome, and perspectives on cardiac tissue engineering. [Nature Reviews Cardiology] |
|
|
|
|
| Rocket Pharmaceuticals, Inc. announced that the US FDA has lifted the clinical hold on the company’s Phase I clinical trial of RP-A501 for the treatment of Danon Disease, allowing patient enrollment to resume. RP-A501 is an investigational gene therapy product being developed for Danon Disease and the first potential gene therapy for monogenic heart failure. [Rocket Pharmaceuticals, Inc.] |
|
|
|
|
| October 19, 2021 London, England, United Kingdom |
|
|
|
|
|
| European Centre Study Diabetes – Strasbourg, France |
|
|
|
| National University of Ireland, Galway – Galway, Ireland |
|
|
|
| Stanford University – Palo Alto, California, United States |
|
|
|
| The University of Tennessee Health Science Center – Memphis, Tennessee, United States |
|
|
|
| Buck Institute for Research on Aging – Novato, California, United States |
|
|
|
|